Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Regulatory
221 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Tafasitamab | EU EMA | Diffuse Large B-Cell Lymphoma | Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).conditional | approved | Aug 26, 2021 | ema |
| Talquetamab | EU EMA | Multiple Myeloma | Talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti CD38 antibody and have demonstrated disease progression on the last therapy.conditional | approved | Aug 21, 2023 | ema |
| Teclistamab | EU EMA | Multiple Myeloma | Tecvayli is indicated in combination with daratumumab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. | approved | Aug 23, 2022 | ema |
| Thalidomide | EU EMA | Multiple Myeloma | Thalidomide Lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ? 65 years or ineligible for high dose chemotherapy. Thalidomide Lipomed is prescribed and dispensed in accordance with the Thalidomide Lipomed Pregnancy Prevention Programme (see section 4.4). | approved | Sep 19, 2022 | ema |
| Thalidomide | EU EMA | Multiple Myeloma | Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4). | approved | Apr 16, 2008 | ema |
| Vorasidenib | EU EMA | Grade 2 Follicular Lymphoma | Voranigo as monotherapy is indicated for the treatment of predominantly non‑enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy (see section 5.1). | approved | Sep 17, 2025 | ema |
Data updated 16 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Dasatinib | 39 | 27 | 12 |
| Venetoclax | 32 | 0 | 32 |
| Mercaptopurine | 31 | 2 | 28 |
| Imatinib | 30 | 28 | 2 |
| Doxorubicin | 29 | 1 | 28 |
| Thioguanine | 29 | 0 | 28 |
| Melphalan | 24 | 0 | 24 |
| Crizotinib | 16 | 11 | 5 |
| Cytarabine | 13 | 3 | 10 |
| Tazemetostat | 13 | 13 | 0 |
| Prednisone | 11 | 11 | 0 |
| Ibrutinib | 10 | 4 | 6 |
| Methotrexate |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 10 |
| 2 |
| 8 |
| Vemurafenib | 10 | 9 | 1 |
| Asparaginase | 9 | 0 | 9 |
| Daunorubicin | 9 | 1 | 8 |
| Chemotherapy | 7 | 7 | 0 |
| Ponatinib | 7 | 6 | 1 |
| Nilotinib | 5 | 4 | 1 |
| Ruxolitinib | 5 | 5 | 0 |
| Arabinosylguanine | 4 | 1 | 3 |
| Gemcitabine | 4 | 0 | 4 |
| Larotrectinib | 4 | 4 | 0 |
| Midostaurin | 4 | 3 | 1 |
| Nelarabine | 4 | 1 | 3 |
| R3Mab | 4 | 4 | 0 |
| Bosutinib | 3 | 2 | 1 |
| Ceritinib | 3 | 1 | 2 |
| GSK126 | 3 | 3 | 0 |
| Palbociclib | 3 | 3 | 0 |
| Prednisolone | 3 | 0 | 3 |
| Letetresgene Autoleucel | 2 | 2 | 0 |
| Lometrexol | 2 | 2 | 0 |
| Pemigatinib | 2 | 2 | 0 |
| R-CHOP Regimen | 2 | 1 | 1 |
| Salinomycin | 2 | 2 | 0 |
| Sirolimus | 2 | 2 | 0 |
| Sunitinib | 2 | 2 | 0 |
| Vincristine | 2 | 1 | 1 |
| Adavosertib | 1 | 1 | 0 |
| Alemtuzumab | 1 | 1 | 0 |
| ALK Inhibitor TAE684 | 1 | 1 | 0 |
| Asciminib | 1 | 1 | 0 |
| Atezolizumab | 1 | 1 | 0 |
| Axitinib | 1 | 0 | 1 |
| Azathioprine | 1 | 0 | 0 |
| BCR-ABL Inhibitor HS-10382 | 1 | 1 | 0 |
| Bortezomib | 1 | 1 | 0 |
| Camptothecin | 1 | 1 | 0 |
| CHZ868 | 1 | 1 | 0 |
| Cisplatin | 1 | 1 | 0 |
| Crenolanib | 1 | 1 | 0 |
| Dexamethasone | 1 | 1 | 0 |
| Dinaciclib | 1 | 0 | 1 |
| Dovitinib | 1 | 1 | 0 |
| EPZ011989 | 1 | 1 | 0 |
| Erdafitinib | 1 | 1 | 0 |
| Erlotinib | 1 | 1 | 0 |
| Etoposide | 1 | 1 | 0 |
| Fludarabine | 1 | 1 | 0 |
| Galiximab | 1 | 1 | 0 |
| Gefitinib | 1 | 1 | 0 |
| GW-2580 | 1 | 1 | 0 |
| HDAC Inhibitor OBP-801 | 1 | 1 | 0 |
| HyperCVAD Regimen | 1 | 1 | 0 |
| I-BET151 | 1 | 1 | 0 |
| Imatinib Mesylate | 1 | 1 | 0 |
| IMG-2005-5 | 1 | 1 | 0 |
| Ipilimumab | 1 | 1 | 0 |
| IRAK-1/4 Inhibitor | 1 | 1 | 0 |
| Irinotecan | 1 | 1 | 0 |
| JAK Inhibitor I | 1 | 1 | 0 |
| JQ-1 | 1 | 1 | 0 |
| JQ1 | 1 | 1 | 0 |
| JQEZ5 | 1 | 1 | 0 |
| Lenalidomide | 1 | 0 | 1 |
| Mcl-1 Inhibitor MIK665 | 1 | 1 | 0 |
| MTOR Inhibitor | 1 | 1 | 0 |
| NCT00137111 | 1 | 1 | 0 |
| Nirogacestat | 1 | 1 | 0 |
| Not Applicable | 1 | 0 | 0 |
| Olaparib | 1 | 1 | 0 |
| Panobinostat | 1 | 1 | 0 |
| Pomalidomide | 1 | 0 | 1 |
| Selumetinib | 1 | 1 | 0 |
| Sorafenib | 1 | 1 | 0 |
| Therapeutic Glucocorticoid | 1 | 0 | 1 |
| Tisagenlecleucel | 1 | 0 | 1 |
| Tofacitinib | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor | 1 | 1 | 0 |
| Vandetanib | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.